Welcome to the
World of AWAWA
Creating Sustainability towards High Quality of Life
Sustainability to Regeneration
Adherence to UN SDGs (SDG 3+)
AWAWA inspires action, serves donors and supports communities in alignment with United Nations and its 17 Sustainable Development Goals. We’re driven by a firm belief in the power of humanity, and we provide long-term solutions and benefits for those who may need assistance in pursuing their dreams.
At AWAWA, we are inspired each day by the work we do, and feel such a sense of accomplishment with each success story that comes from past or present recipients. Sometimes, the best solutions come from the people who are most affected by the problem — and we want to be the center stage of their success.
About AWAWA
Dedicated to Enhancing Quality of Life
As a leading regenerative medicine-oriented and non-profit organisation in the Asia Pacific region, backed by numerous world-known institutions and organisations including but not limited to China Regenerative Medicine, Forall Biotech, Healios, Gwoxi Stem Cell Applied Technology, Global Citizen Capital, MitoBioMed and StemGenn Therapeutics, Asia World Anti-Aging and Well-Being Association has been at the forefront of making a difference in the community. We support the passion of researchers, scientists, professors doctors and other professionals who want to create a lasting change by addressing the causes of our greatest challenge - that of quality of life maintenance throughout one's entire lifetime
Elevating Talent
Striving To Make a Difference
Founded in 2015, AWAWA has become an important part of the regenerative medicine community in Asia and beyond. Working hard to help recipients from all over the world — our contributions go towards helping make people’s dreams come true. At AWAWA, we value the essence of giving and go the extra mile to provide those in need with a wide range of opportunities that will allow them to reach their potential.
Recent News
All the Latest Updates In One Place
Coronavirus Update
AWAWA and two of its affiliated companies: Forall Biotech and MitoBioMed have officially joined #China and its national #coronavirus initiative.
First work stream: utilize molecular medicine research to prevent the virus from replication
Second work stream: mobilize proven cellular rejuvenation technology to boost immunity of infected patients
3D Organ Printing
While the most obvious application of 3D printing to the medical industry may be prosthetics, additive manufacturing is changing medical science in more ways than you might think. Like something out of a science fiction film, researchers are now able to 3D print organs. According to our friends over at IDTechEx, 3D bioprinting has recently gained tremendous momentum with an equal amount of innovation happening both on the commercial side and in academic research; and this is just the beginning.
Vestibular Disorders
Researchers at the Stanford University School of Medicine have found a way to regenerate hair cells in the inner ears of mice, allowing the animals to recover vestibular function. It’s the first time such recovery has been observed in mature mammals. If further research shows that the technique can be applied to humans, it would be an initial step toward treating vestibular disorders, such as dizziness. There is currently no effective treatment for dizziness and balance disorders caused by damaged or lost vestibular hair cells. The only available therapy is teaching patients coping mechanisms through physical therapy.
(CAR) T-cell therapy
The Center for iPS Cell Research and Application (CiRA) at Kyoto University and Takeda Pharmaceutical Company Limited today announced that a novel induced pluripotent stem (iPS) cell-derived chimeric antigen receptor (CAR) T-cell therapy (iCART) has been transferred from their T-CiRA research collaboration to Takeda as the program begins process development toward clinical testing. Under the terms of the T-CiRA agreement, Takeda has the global rights to develop and commercialize the iCART product and CiRA will receive development and approval milestones.
